Abstract: A system for alimentary instruction sets derived from artificial intelligence systems for vibrant constitutional guidance, as derived using one or more machine-learning procedures from training data relating prognostic and ameliorative labels. A physical performance instruction set is derived from the alimentary instruction sets using one or more physical performance entity profiles.

Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.

Abstract: The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA.

Abstract: Described herein are oral care compositions comprising a crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, together with a blue to violet-blue pigment; including some embodiments which further comprise an ethylene oxide, propylene oxide block co-polymer.

Abstract: Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods.

Abstract: A method of treating or protecting a mammalian teat by applying a topical composition to the teat, wherein the topical conditioning composition comprises (a) citrate; (b) methylene blue; and (c) an alkyl para-hydroxybenzoate; as well as related methods and compositions.

Abstract: A disposable paper towel with an anti-microbial lotion and is provided with a chromatic transfer indicator which undergoes a delayed, visually perceptible color change at a predetermined time after the towel is wetted. An anti-microbial lotion on the towel increases water absorbency times (WAR) to further promote lotion transfer to the skin and increase lotion transfer effectiveness.

Abstract: A method for providing anesthesia to a subject having a wound, such as a laceration, a surgical incision, an ulcer, an abrasion or a burn, said method comprising the step of applying topically to the wound a composition comprising: at least one local anesthetic agent; a hydrophilic or hydroalcoholic gelling agent; an antiseptic agent; a vasoconstrictor; and a detectable marker such as a food dye, wherein when the composition is topically applied to the wound of the subject the presence of the anesthetic agent on the subject is indicated by the detectable marker. The method has been developed primarily for anaesthetizing open wounds of animals, particularly those caused by husbandry procedures.

Abstract: The present invention relates to a disinfectant solution, comprising an oxidative and reductive potential (ORP) solution and a colorant. A disinfectant article, a method of forming the disinfectant solution and use of the disinfectant solution are also provided.

Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.

Abstract: A remote treatment delivery system for an animal including a dosage projectile adapted to deliver a biologically active agent to an animal substantially without piercing the skin of the animal and containing a biologically active agent and a carrier in liquid or gel form, the carrier allows adhesion of the biologically active agent to skin, coat or fur of the animal; wherein the agent and the carrier are encapsulated in one or more encapsulating agents; and wherein the encapsulating agents forms a frangible shell.

Abstract: A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).

Abstract: The present invention provides methods of administering an active agent to a specifically identified area of mucous membrane of a human being, as well as a body dissolving film formed therefore.

Abstract: The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent.

Abstract: The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

Abstract: A device may comprise first matter including a first material adapted, when in contact with a liquid, to clean the liquid and to maintain the liquid at a first color. The device may include second matter including a second material adapted, when in contact with the liquid, to maintain the liquid at a second color. The device may further include an interface configured to limit an exposure of the second material to the liquid before at least a portion of the first material contacts the liquid.

Abstract: Use of a moulding composition comprising a polymer and a setting agent for wound debridement, wherein said use comprises adding water to said moulding composition to form a moulding fluid, applying said moulding fluid to a surface of a wound, allowing said moulding fluid to set in contact with said surface to form a solid covering on said surface, followed by removing said solid covering from the wound. The alginate composition adheres strongly to bacterial biofilms on the wound, whereby the biofilms are removed with the alginate composition. The moulding composition may be used in conjunction with a staining agent that undergoes a colour change in the presence of bacteria or bacterial polysaccharides to show the presence and removal of the biofilm. Also provided are methods of treating wounds using the compositions.

Abstract: Provided herein in some embodiments is a formulation comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. In some instances, the formulation is an immediate and sustained released formulation suitable for topical administration or administration to surfaces. Also provided here in certain embodiments is a method of reducing the population of pathogenic microorganisms on skin or surfaces, the method comprising applying to the skin or surface a composition, the composition comprising (a) one or more nanoscale particle; and (b) a film-forming polymer.

Abstract: Oral care compositions and methods are described in which the composition includes a chalcone color change component, which may be phenyl-3-methoxy-4-hydroxystyryl ketone. The color change component is induced to change colors by addition of saliva and/or by a change in pH of the composition. The composition and methods provide benefits including providing visual cues to the user.

Abstract: A reversible color-changing ink formulation, and a nonwoven wipe to which the ink formulation is securely bound, are provided. The reversible color-changing ink formulation includes about 55-98% by weight of a polymer binder, about 0.1-20% by weight of a reversible color-changing dye that reversibly changes between a first color and a second color at a pH of about 5.5 to about 8.0, and optional amounts of plasticizer, inorganic particulate filler, and color brightener. During use, the nonwoven wipe is impregnated with a sanitizer solution that contains a quaternary ammonium compound. The nonwoven wipe reversibly changes between a first color when impregnated with the sanitizer solution and a second color when the sanitizer solution is depleted during use. The change to the second color indicates the need to recharge the nonwoven wipe with the sanitizer solution, whereupon the first color returns.

Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.

Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.

Abstract: An ink formulation having a marking component and a reduced indium tin oxide (r-ITO) is disclosed. The r-ITO in powder form exhibits a lightness (L*), according to the 1976 CIE (L*, a*, b*) space, of not more than 50.

Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.

Abstract: The present invention monitors an IV bag injection port and informs the user of prior injections. The present invention employs an object and/or a sealed chamber within a transparent IV fluid bag injection port. In the case of the object, notification of prior use is achieved when the object's or IV fluid's appearance is altered. With respect to the sealed chamber, the chamber's seal is breached to allow fluid to pass between the chamber and the IV bag to change the appearance of the contents of the chamber. Since the injection port and bag walls are at least partially transparent, medical personnel are able to observe the altered appearance of either the object, IV fluid or the sealed chamber.

Abstract: Provided herein is a prenatal and postpartum multivitamin and mineral supplement package provided in the form of a plurality of solid oral dosage units individually contained in blister packs wherein a portion of the dosage forms are iron-containing while at least half of the dosage units are essentially iron-free and wherein the total amount of iron in the package as sold to purchasers is less than about 1300 mg of elemental iron.

Abstract: The invention discloses compositions and formulations for the treatment of clean or infected wounds, some of the inventive formulations can be used to reduce or eliminate microbial contamination from surfaces such as skin, and inanimate objects such as countertops, cooking utensils, medical devices, cookware, food, grooming aids and agricultural biocides, and the like. Some of these compositions and formulations are well suited for use in wound dressings. Some of the formulation can kill and/or inhibit the growth of pathogenic bacteria, fungi, spores and viruses. The formulations comprise a compound such as an osmoticum in high enough concentration to create an osmotic gradient and at least one compound that acts to comprise the integrity of a microorganism's membrane or cell wall. These formulations may optimally include at least one agent that thickens the formulations. In some aspects the formulation is in the form of an emulsion.

Abstract: The present invention provides methods of administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as oral dissolving film formed therefore.

Abstract: The present invention relates to rapidly dissolving edible film dosage form incorporating a physical-chemical identifier and/or indicia. The physical-chemical identifier and/or indicia may correspond to an active ingredient that may be evenly distributed throughout the film. The physical-chemical identifier and/or indicia may be associated with at least one section of the film composition and/or associated with a sealed pouch or package containing the film composition and provide information to the consumer, practitioner, producer or regulator that is relevant to the edible film dosage form.

Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.

Abstract: There is provided a personal care product having a body side liner, a baffle and an indicator strip with two ends. The indicator has an amine sensitive dye near at least one end. The indicator extends from the target area just below the liner to just above the baffle such that the dye deposit is visible to an unaided eye. The dye changes color in the presence of amines which are characteristic of infection, thus alerting the user to the possibility of infection. Such an indicator placed in a feminine hygiene pad, for example, may be useful in the diagnosis of vaginits.

Abstract: Anti-viral tissues are provided with a pH indicator which can communicate to a tissue user by means of visual indicia, via color changes, that the tissue has active ingredients. Furthermore, the pH indicators can be used to illustrate neutralization of the pH of infected nasal discharge, which has a higher pH than healthy nasal discharge, giving the user a reason to believe that the product is working to deactivate virus.

Abstract: A method of remotely treating an animal including launching a delivery system at the animal, wherein the delivery system comprises a dosage projectile adapted to deliver a biologically active agent to an animal substantially without piercing the skin of the animal and containing a biologically active agent and a transdermal carrier in liquid or gel form, wherein the agent and the carrier are encapsulated in one or more encapsulating agents, and wherein the encapsulating agents forms a frangible shell; impacting the projectile on the animal to release the biologically active agent and the transdermal carrier from the frangible shell substantially without piercing the skin of the animal; and delivering the biologically active agent to the animal, wherein the transdermal carrier facilitates passage of the biologically active agent across the skin of the animal to provide treatment to the animal.

Abstract: Embodiments disclosed herein relate to thermostable storage of one or more therapeutic agents, including at least one detectable indicator. In an embodiment, the one or more therapeutic agents including at least one detectable indicator are included in at least one glassy substance. Also disclosed are embodiments relating to delivery devices for administration of the thermostable therapeutic agents.

Abstract: The present disclosure teaches unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable.

Abstract: The present invention provides a concentrate for dilution with water in the preparation of an agricultural composition for application to crops, soil or animals. The concentrate is recommended for use with agricultural chemicals whose agricultural activity varies with the pH of the water. It comprises an active ingredient and a combination of pH indicators for coloring the water, the pH indicators being selected so as to indicate different colors of spray water at different pH levels. The proportions of active ingredient and pH indicators are selected so that when the concentrate is added to water, the pH indicators indicate visually upper and lower pH limits for optimum activity of the agricultural chemical.

Abstract: Provided herein in some embodiments is a formulation comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. In some instances, the formulation is an immediate and sustained released formulation suitable for topical administration or administration to surfaces. Also provided here in certain embodiments is a method of reducing the population of pathogenic microorganisms on skin or surfaces, the method comprising applying to the skin or surface a composition, the composition comprising (a) one or more nanoscale particle; and (b) a film-forming polymer.

Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.

Abstract: Orally disintegrating tablets containing colored granules of a water-soluble sugar which give them a speckled appearance are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, nurses and patients.

Abstract: The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof; it also relates to the use of these compounds for combating chemical submission and to a method for combating chemical submission using said pharmaceutical forms.

Abstract: The present invention relates to a method for combating chemical submission, which comprises: putting into solution, in a beverage, a pharmaceutical form comprising an active ingredient and at least 0.05 mg, preferably from 0.2 to 5 mg, even more preferentially from 0.3 to 2 mg of at least one water-soluble colouring agent chosen from: indigocarmine or E 132, erythrosine or E 127, brilliant blue FCF, alphazurine FG, fast green FCF, quinzarine green SS, orange II, tartrazine and Sunset yellow FCF, detecting the pharmaceutical form, said detection being characterized by the immediate change in colour of the beverage; it also relates to the use of said colorant for combating chemical submission, and also to a non-film-coated solid pharmaceutical form comprising said colorant.

Abstract: An oral solid preparation including a base compound and a powdery or granular additive colored with a colorant and a method of manufacturing an oral solid preparation including the steps of: coloring an additive with a colorant, mixing the resultant additive with a base compound, and tableting the mixture.

Abstract: A disposable paper towel with an anti-microbial lotion and is provided with a chromatic transfer indicator which undergoes a delayed, visually perceptible color change at a predetermined time after the towel is wetted. An anti-microbial lotion on the towel increases water absorbency times (WAR) to further promote lotion transfer to the skin and increase lotion transfer effectiveness.

Abstract: The composition is a blood clotting composition including at least one hemostatic agent and an indicator agent that adheres to the skin on or around the wound, the indicator agent being specifically identifiable to the hemostatic composition. The composition can be adapted to be applied to a wound as an emergency trauma treatment in homes, public places, trauma treatment centers, at accident locations, in the field of military combat, or any other potential site of severe trauma as a first response to reduce or stop bleeding. The composition can include at least one clotting agent, an analgesic, a bactericide (such as silver), and at least one antibiotic. An applicator device for the composition is included.

Abstract: A skin care composition with indicating function including a skin care component, a pH indicator and a buffer solution is provided. The skin care composition has a pH value less than or equal to 8. A method of using the skin care composition includes the following. The skin care composition is applied on a skin surface. After the skin care composition is applied on the skin surface for a period of time, the color of the skin care composition changes. When the color of the skin care composition changes, the skin care composition is removed from the skin surface.

Abstract: A method of treating or protecting a mammalian teat by applying a topical composition to the teat, wherein the topical conditioning composition comprises (a) citrate; (b) methylene blue; and (c) an alkyl para-hydroxybenzoate; as well as related methods and compositions.

Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a stable antiseptic solution comprising: a di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof, wherein said di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to a process for preparing said antiseptic solution.

Abstract: Embodiments disclosed herein relate to thermostable storage of one or more therapeutic agents, including at least one detectable indicator. In an embodiment, the one or more therapeutic agents including at least one detectable indicator are included in at least one glassy substance. Also disclosed are embodiments relating to delivery devices for administration of the thermostable therapeutic agents.

Abstract: An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.